Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $166.71 billion. The enterprise value is $221.02 billion.
| Market Cap | 166.71B |
| Enterprise Value | 221.02B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | May 16, 2024 |
Share Statistics
Amgen has 536.43 million shares outstanding. The number of shares has decreased by -0.37% in one year.
| Shares Outstanding | 536.43M |
| Shares Change (YoY) | -0.37% |
| Shares Change (QoQ) | -0.37% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 80.99% |
| Float | 534.90M |
Valuation Ratios
The trailing PE ratio is 44.33 and the forward PE ratio is 14.90. Amgen's PEG ratio is 2.39.
| PE Ratio | 44.33 |
| Forward PE | 14.90 |
| PS Ratio | 5.64 |
| Forward PS | 4.88 |
| PB Ratio | 33.20 |
| P/FCF Ratio | 23.49 |
| PEG Ratio | 2.39 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.31, with an EV/FCF ratio of 31.14.
| EV / Earnings | 58.74 |
| EV / Sales | 7.48 |
| EV / EBITDA | 18.31 |
| EV / EBIT | 29.47 |
| EV / FCF | 31.14 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 12.75.
| Current Ratio | 1.42 |
| Quick Ratio | 0.84 |
| Debt / Equity | 12.75 |
| Debt / EBITDA | 5.30 |
| Debt / FCF | 9.02 |
| Interest Coverage | 2.38 |
Financial Efficiency
Return on equity (ROE) is 58.60% and return on invested capital (ROIC) is 8.74%.
| Return on Equity (ROE) | 58.60% |
| Return on Assets (ROA) | 4.10% |
| Return on Capital (ROIC) | 8.74% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | $140,936 |
| Employee Count | 26,700 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 1.45 |
Taxes
In the past 12 months, Amgen has paid $582.00 million in taxes.
| Income Tax | 582.00M |
| Effective Tax Rate | 13.39% |
Stock Price Statistics
The stock price has increased by +38.11% in the last 52 weeks. The beta is 0.60, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.60 |
| 52-Week Price Change | +38.11% |
| 50-Day Moving Average | 301.76 |
| 200-Day Moving Average | 285.43 |
| Relative Strength Index (RSI) | 55.10 |
| Average Volume (20 Days) | 2,432,329 |
Short Selling Information
The latest short interest is 9.12 million, so 1.70% of the outstanding shares have been sold short.
| Short Interest | 9.12M |
| Short Previous Month | 9.05M |
| Short % of Shares Out | 1.70% |
| Short % of Float | 1.71% |
| Short Ratio (days to cover) | 4.12 |
Income Statement
In the last 12 months, Amgen had revenue of $29.53 billion and earned $3.76 billion in profits. Earnings per share was $7.01.
| Revenue | 29.53B |
| Gross Profit | 19.60B |
| Operating Income | 6.97B |
| Pretax Income | 4.35B |
| Net Income | 3.76B |
| EBITDA | 12.07B |
| EBIT | 7.50B |
| Earnings Per Share (EPS) | $7.01 |
Balance Sheet
The company has $9.71 billion in cash and $64.02 billion in debt, giving a net cash position of -$54.31 billion or -$101.25 per share.
| Cash & Cash Equivalents | 9.71B |
| Total Debt | 64.02B |
| Net Cash | -54.31B |
| Net Cash Per Share | -$101.25 |
| Equity (Book Value) | 5.02B |
| Book Value Per Share | 9.36 |
| Working Capital | 8.32B |
Cash Flow
In the last 12 months, operating cash flow was $8.10 billion and capital expenditures -$998.00 million, giving a free cash flow of $7.10 billion.
| Operating Cash Flow | 8.10B |
| Capital Expenditures | -998.00M |
| Free Cash Flow | 7.10B |
| FCF Per Share | $13.24 |
Margins
Gross margin is 66.37%, with operating and profit margins of 23.59% and 12.74%.
| Gross Margin | 66.37% |
| Operating Margin | 23.59% |
| Pretax Margin | 14.71% |
| Profit Margin | 12.74% |
| EBITDA Margin | 40.87% |
| EBIT Margin | 25.40% |
| FCF Margin | 24.03% |
Dividends & Yields
This stock pays an annual dividend of $9.00, which amounts to a dividend yield of 2.90%.
| Dividend Per Share | $9.00 |
| Dividend Yield | 2.90% |
| Dividend Growth (YoY) | 7.62% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 128.39% |
| Buyback Yield | 0.37% |
| Shareholder Yield | 3.27% |
| Earnings Yield | 2.26% |
| FCF Yield | 4.26% |
Analyst Forecast
The average price target for Amgen is $306.68, which is -1.32% lower than the current price. The consensus rating is "Buy".
| Price Target | $306.68 |
| Price Target Difference | -1.32% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 5.00% |
| EPS Growth Forecast (5Y) | 12.43% |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.41 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.41 |
| Piotroski F-Score | 5 |